Antibiotikaprofylax vid kirurgiska ingrepp - SBU

Table 4.12.4 Transrectal prostatic biopsy (TPB).
Author
Year
Reference
Country
Study
design
Population
characteristics
Intervention
Method
Number individuals
Control
Number
individuals
Results
Withdrawal
Drop outs
Study quality
and relevance
Comments
Aron
2000
[17]
India
RCT
Transrectal core
prostate biopsy.
Follow-up 48 h
after biopsy
I1: Singel dos Ciproflox
500 mg + tinidazol 600 mg po
+ placebo until 3 days (n=79)
I2: Ciprofloxacin 500 mg
+ tinidazol 600 mg po for
3 days (n=77)
C: Placebo 3 days
(n=75)
Bacteriuri
I1: 4/79 (5%)
I2: 6/77 (7.8%)
C: 14/75 (18.7%)
I1 vs C: p=0.01
I1 vs I2: ns
Not
indicated
High
Fever/bacteraemia/prostatitis
I1: 2/0/8
I2: 2/1/3
C: 5/2/6
Aus
1996
[18]
Sweden
RCT
Transrectal core prostate
biopsy. No special patient
selection. Risk factor
analysis included.
n=500
I: Norfloxacin 400 mg x 2
for 1 day (n=245)
C: Norfloxacin
400 mg x 2 for
1 week (n=246)
Symptomatic UTI
I: 27/245 (11%).
12/27 had fever
C: 12/246 (4.9%).
7/12 had fever
Infection in patients
I: With RF: 15/84 (17.9%)
With no RF: 12/161 (7.5%)
C: With RF: 3/90 (3.3%)
With no RF: 9/156 (5.8%)
2% High
One week norfloxacin
superior
to 1 day. The most
pronounced effect
was seen in patients
with any RF (indwelling
catheter, history
UTI or prostatitis,
diabetes)
Briffaux
2009
[19]
France
RCT
Transrectal core prostate
biopsy. Negative urine
culture and no risk factors.
Evaluation at 5 days after
biopsy
I: Single dose 1 g ciprofloxacin
orally (n=139)
C: Ciprofloxacin
500 mg x 2 for
3 days (n=149)
Asymptomatic bacteriuri
I: 6/139 (4.5%)
C: 6/149 (4.2%)
ns
Acute prostatitis
I: 1/139 (0.75%)
C: 1/149 (0.7%)
ns
10% High
The table continues on the next page
454 antibiotikaprofylax vid kirurgiska ingrepp KAPITEL 4 • den systematiska litteraturöversikten
455